# Guojin Group

> Guojin Group is a VC fund in Yangzhou backing Biotechnology and Pharmaceutical. See 5 investments, check sizes, portfolio. Updated Aug 2026.

- Type: VC Fund
- Location: Yangzhou, China
- Total investments: 5
- Last investment: Mar 2026
- Lead investor: 20%
- Last updated: Aug 2026
- Website: https://yzgjtz.com

Guojin Group is an investment firm that focuses on financial investment and operates within the financial services sector.

## Investment focus

### Industry

| Industry | Investments | Share |
| --- | --- | --- |
| Biotechnology | 3 | 60% |
| Pharmaceutical | 3 | 60% |
| Medical | 2 | 40% |
| Automotive | 1 | 20% |
| Industrial | 1 | 20% |

13 industries tracked in total.

### Stage

| Stage | Investments | Share |
| --- | --- | --- |
| Series C | 2 | 40% |
| Series B | 1 | 20% |
| Series D | 1 | 20% |
| Venture - Series Unknown | 1 | 20% |

## Investments

| Company | Description | Amount | Stage | Date | Website |
| --- | --- | --- | --- | --- | --- |
| Lips Semiconductor | Lipps is a research and development, production and sales company of power semiconductor components. It can independently design IGBT/SIC, MOSFET modules and IPM module products, and has established a cooperative relationship with Japanese power module packaging factories. | $14.5M | Series B | Mar 16, 2026 |  |
| Novlead Biotech | Novlead Biotech contributes to a safer and healthier human well-being through our technological innovations. |  | Series C | Apr 15, 2025 |  |
| Alebund Pharmaceuticals | Alebund Pharmaceuticals is a biopharmaceutical company dedicated to developing innovative therapies for the treatment of renal diseases and related chronic conditions. | $75.1M | Series C | Jan 07, 2025 |  |
| Singlera | Singlera is a medical firm that is working to overcome the delay in early diagnosis of cancer through screening and auxiliary. | $13.8M | Venture - Series Unknown | Jul 05, 2024 |  |
| IMPACT Therapeutics | IMPACT Therapeutics is dedicated to the development of similar drugs to treat cancer have independent intellectual property rights and other diseases of the best (best-in-class) of new drugs and its commercialization. The company's senior management team of experienced and professional background complementary and have accumulated more thanfour decades of experience in drug development and management. General Manager and Chief Scientific Officer Field are an expert in pharmacology and biology. | $55.3M | Series D | Apr 19, 2024 |  |

5 of 5 investments shown.

## Co-investors
- [Kingray Capital](https://shizune.co/investors/profile/kingray-capital) — VC Fund, 2 deals together
- [ShenZhen GTJA Investment Group](https://shizune.co/investors/profile/shenzhen-gtja-investment-group) — VC Fund, 2 deals together
- [C&D Emerging Investment](https://shizune.co/investors/profile/c-d-emerging-investment) — VC Fund, 1 deal together
- [Dingxin Capital](https://shizune.co/investors/profile/dingxin-capital) — VC Fund, 1 deal together
- Economic Development Investment — VC Fund, 1 deal together
- [EFung Capital](https://shizune.co/investors/profile/efung-capital) — VC Fund, 1 deal together

## Similar investors

### Similar stage
- [Sequoia Capital](https://shizune.co/investors/profile/sequoia-capital) — VC Fund
- [New Enterprise Associates](https://shizune.co/investors/profile/new-enterprise-associates) — VC Fund
- [Bessemer Venture Partners](https://shizune.co/investors/profile/bessemer-venture-partners) — VC Fund

## FAQ

### What does Guojin Group invest in?

Guojin Group invests primarily in Biotechnology, Pharmaceutical and Medical startups, most often at Series C and Series B stage. Most of the 5 investments tracked by Shizune back companies in China. The Investment Focus section breaks down every industry, stage and country in the portfolio.

### When did Guojin Group last invest?

The most recent investment recorded for Guojin Group closed in Mar 2026. Shizune tracks 5 investments in total for this profile, including round sizes, stages and portfolio companies, all sourced from confirmed public funding rounds and refreshed monthly.

### Is Shizune's investor data accurate?

Yes — every stat on this profile is calculated from confirmed public funding rounds monitored across hundreds of sources since 2020. This profile was last refreshed in Aug 2026 and is updated monthly. Spotted something off? Use the “Suggest an edit” link near the top of the page.

# About Shizune
Shizune.co is an investor database. Core features:
- 48,091 startup investors (angels, VCs, accelerators, and others)
- Email, phone, LinkedIn (for intros), socials, and other contact data
- Updated daily from public funding news
- CSV and Excel export

The User can access the full database FOR FREE after signing up: shizune.co